Anavex Life Sciences Corp (AVXL)

[WolfofMia]

Cool, now do one where Dr. Kun Jin, who was recently appointed as Vice President, Head of Biostatistics at Anavex Life Sciences Corp is part of a company releasing this PR for the AD trial:

The trial is successful in meeting the co-primary endpoints if the significance of each endpoint is P < 0.05, or if the significance of only one co-primary endpoint is P < 0.025. If only one primary endpoint is significant at an a level of 0.025, then the secondary endpoint will be evaluated at the same level of 0.025. The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226) for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early Alzheimer’s disease.

MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing treatment to placebo.